ARGENX SE (ARGX) Form 6-K — Aug 27, 2026
argenx SE completed its acquisition of Forte Biosciences on August 27, 2026, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, to its immunology pipeline. The deal closed through a cash tender offer at $77.00 per share, with 19,894,879 Forte shares validly tendered; together with shares already owned by argenx and its affiliates, that represented approximately 87.13% of Forte's outstanding stock. A follow-on merger made Forte a wholly owned argenx subsidiary, and Forte stock no longer trades on the Nasdaq Capital Market.
Key figures
- Shares Validly Tendered
- 19894879
- Tender Offer Expiration
- one minute after 11:59 p.m. ET, August 26, 2026
- Phase2 Celiac Data Expected
- second half of 2026
- Tender Offer Price Per Share
- $77.00
- Vitiligo Trial Data Reported
- July 2026
- Phase1b Alopecia Areata Data Expected
- second half of 2026
- Tendered Plus Argenx Affiliate Ownership Percent
- 87.13%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.